Trials / Unknown
UnknownNCT04270071
Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris
Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris: Randomised, Double Blind, Placebo Controlled Trial
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Academic / Other
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, double-blind, placebo-controlled, parallel clinical trial in Chinese population with stable angina pectoris. The purpose is to determine the efficacy and safety of Yangxin Shengmai Granules in the treatment of stable angina pectoris.
Detailed description
Yangxin Shengmai granules is a Chinese patent medicine composed of ginseng, Ophiopogon japonicus, Salvia miltiorrhiza, Schisandra chinensis, etc. It is used for the treatment of chest pain caused by Qi-yin deficiency and blood stasis in traditional Chinese medicine. The symptoms include chest tightness, chest pain, palpitation, shortness of breath, fatigue, dry mouth and dry throat. Clinical applications suggested that Yangxin Shengmai granules were safe and effective in the treatment of coronary heart disease. However, high-quality clinical trials are still needed to further confirm, so as to provide theoretical basis for the treatment of stable angina pectoris with traditional Chinese medicine. The study is designed to determine the efficacy and safety of Yangxin Shengmai Granules in the treatment of stable angina pectoris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Yangxin Shengmai | Yangxin Shengmai Granules |
| DRUG | Yangxin Shengmai placebo | Yangxin Shengmai placebo have an identical appearance and scent as the active treatment granules. |
| DRUG | nitroglycerin tablets | Be used when angina attack |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2021-10-01
- Completion
- 2021-12-01
- First posted
- 2020-02-17
- Last updated
- 2020-11-13
Source: ClinicalTrials.gov record NCT04270071. Inclusion in this directory is not an endorsement.